Table 2.
Groups | AM IPI (min) | PM IPI (min) | AM Amplitude (pg/ml) | PM Amplitude (pg/ml) |
---|---|---|---|---|
Lesions (N = 6) | ||||
15–17 months | 137.7±35.1# | 114.7±11.5 | 1.4±0.2 | 1.3±0.2 |
18–20 months | 47.7±5.1**,a | 51.2±1.6***,aa | 3.4±1.0*,a | 5.0±1.6*,a |
21–24 months | 55.0±5.2***,a | 50.2±2.6*** | 5.1±1.3*,a | 6.6±1.4**,a |
25–29 months | 49.6±2.9*** | 54.2±3.1*** | 8.6±3.1* | 10.6±3.2* |
30–3å4 months | 56.4±2.1*** | 54.3±3.6*** | 7.4±2.6* | 8.7±1.5** |
> 35 months | 44.5±3.3*** | 48.4±1.3*** | 11.6±5.0* | 14.2±5.0* |
| ||||
Sham/controls (N=5) | ||||
15–17 months | 135.7±16.8 | 99.2±15.6 | 1.3±0.3 | 1.2±0.1 |
18–20 months | 132.0±30.9 | 122.0±23.1 | 1.5±0.3 | 1.8±0.8 |
21–24 months | 115.2±19.4 | 73.2±9.1 | 2.0±0.3 | 1.8±0.8 |
25–29 months | 71.8±8.6** | 58.0±3.6* | 2.1±0.4 | 4.8±1.4* |
30–34 months | 54.3±3.6*** | 51.1±5.1** | 9.3±3.5* | 15.7±3.5** |
> 35 months | 57.3±5.2*** | 47.5±3.6** | 7.4±2.6* | 17.1±4.5** |
Mean±SEM
p<0.05 vs. 15–17 months;
p<0.01 vs. 15–17 months;
p<0.001 vs. 15–17 months (within group)
p<0.05 vs. sham/controls at corresponding age;
p<0.01 vs. sham/controls at corresponding age (between groups)